ArticleBMC cancer2026
Elevated levels of SLC38A1 are correlated with an unfavorable prognosis, as well as accelerated cell proliferation and metastasis in lung adenocarcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSLC38A1 has been identified as a carcinogenic factor in the progression of colorectal, gastric, pancreatic, and other cancers. However, its involvement in lung adenocarcinoma (LUAD) remains unexplored in the literature.
methodsThe expression levels, diagnostic relevance, and clinical significance of SLC38A1 in LUAD were evaluated using data from the TCGA, XENA, and LCE databases, along with validation in samples from 10 LUAD patients at our hospital. Prognostic nomograms and risk models based on SLC38A1 were constructed. The functional roles and mechanisms of SLC38A1 in LUAD were investigated through CCK-8 assays, migration and invasion assays, Western blotting, GO and KEGG pathway analyses, and correlation analysis to explore its relationship with the immune microenvironment.
resultsSLC38A1 was overexpressed in both unpaired and paired LUAD samples, with a marked increase in early-stage LUAD. Overexpression of SLC38A1 correlated with diagnostic accuracy and poor overall survival (HR = 1.53; 95% CI = 1.15-2.04), disease-free survival (HR = 1.59; 95% CI = 1.1-2.3), and progression-free interval (HR = 1.51; 95% CI = 1.16-1.97). COX regression analysis identified SLC38A1 overexpression as an independent risk factor for poor prognosis in LUAD patients. High-risk scores and nomograms associated with SLC38A1 were significantly linked to adverse clinical outcomes. Genes co-expressed with SLC38A1 were involved in nuclear division, DNA replication, and the cell cycle. Silencing of SLC38A1 expression inhibited LUAD cell growth and migration. Furthermore, SLC38A1 overexpression was associated with immune cell infiltration in LUAD, including Th2 cells, Tcm, T helper cells, and immune markers such as CD8A, CD8B, and CTLA4.
conclusionSLC38A1 is upregulated in LUAD, and its overexpression is associated with poor prognosis, diagnostic accuracy, and immune cell infiltration. SLC38A1-based risk models and nomograms offer potential predictive tools for assessing prognosis in LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.